Nonomura M, et al. - In neonates with hypoxic-ischemic encephalopathy (HIE), researchers assessed the safety and feasibility of combination therapy with erythropoietin (Epo), magnesium sulfate and hypothermia. In neonates that met the institutional criteria for hypothermia therapy, combination therapy with Epo (300 U/kg every other day for 2 weeks), magnesium sulfate (250 mg/kg for 3 days) and hypothermia was started within 6 hours of birth. In this preliminary study, nine patients were included. According to the results of this pilot prospective study, combination therapy with 300 U/kg Epo every other day for 2 weeks, 250 mg/kg magnesium sulphate for 3 days and therapeutic hypothermia can be performed in newborn HIE patients. No serious adverse deaths or events due to the therapy were observed. Overall, they concluded that combination therapy is feasible in newborns with HIE.